189 related articles for article (PubMed ID: 22825124)
1. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
2. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Seyedmousavi S; Meletiadis J; Melchers WJ; Rijs AJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2013 Feb; 57(2):796-803. PubMed ID: 23183435
[TBL] [Abstract][Full Text] [Related]
3. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2013 Jan; 57(1):303-8. PubMed ID: 23114773
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
van de Sande WW; Mathot RA; ten Kate MT; van Vianen W; Tavakol M; Rijnders BJ; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2009 May; 53(5):2005-13. PubMed ID: 19237647
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.
Perkhofer S; Jost D; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2008 May; 52(5):1873-5. PubMed ID: 18347112
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
10. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.
Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5438-47. PubMed ID: 23959322
[TBL] [Abstract][Full Text] [Related]
11. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of the Orotomides against
Hope WW; McEntee L; Livermore J; Whalley S; Johnson A; Farrington N; Kolamunnage-Dona R; Schwartz J; Kennedy A; Law D; Birch M; Rex JH
mBio; 2017 Aug; 8(4):. PubMed ID: 28830945
[TBL] [Abstract][Full Text] [Related]
14. Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology.
Cafini F; Sevillano D; Alou L; Gómez-Aguado F; Corcuera MT; González N; Guinea J; Prieto J
Rev Esp Quimioter; 2012 Mar; 25(1):47-55. PubMed ID: 22488542
[TBL] [Abstract][Full Text] [Related]
15. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.
Elefanti A; Mouton JW; Verweij PE; Tsakris A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2013 Oct; 57(10):4656-63. PubMed ID: 23856768
[TBL] [Abstract][Full Text] [Related]
17. A New Marker of Echinocandin Activity in an
Meletiadis J; Siopi M; Tsakris A; Mouton JW; Pournaras S
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463527
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
[TBL] [Abstract][Full Text] [Related]
19. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
20. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
